Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. AZN
stocks logo

AZN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.08B
+8.83%
1.142
+15.33%
14.57B
+7.42%
1.109
+6.63%
15.31B
+2.79%
1.019
-2.53%
Estimates Revision
The market is revising Upward the revenue expectations for AstraZeneca PLC (AZN) for FY2025, with the revenue forecasts being adjusted by 0.87% over the past three months. During the same period, the stock price has changed by -8.27%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.06%
In Past 3 Month
Stock Price
Go Down
down Image
-8.27%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 87.14 USD with a low forecast of 75.00 USD and a high forecast of 97.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 70.970
sliders
Low
75.00
Averages
87.14
High
97.00
up Image0
Current: 70.970
sliders
Low
75.00
Averages
87.14
High
97.00
UBS
Matthew Weston
Hold
to
Strong Buy
Upgrades
n/a
2025-02-13
Reason
UBS
Matthew Weston
Price Target
n/a
2025-02-13
Upgrades
Hold
to
Strong Buy
Reason
UBS
Matthew Weston
Strong Sell
to
Hold
Upgrades
n/a
2024-11-20
Reason
UBS
Matthew Weston
Price Target
n/a
2024-11-20
Upgrades
Strong Sell
to
Hold
Reason
Erste Group
Hans Engel
Hold
to
Strong Buy
Upgrades
n/a
2024-09-11
Reason
Erste Group
Hans Engel
Price Target
n/a
2024-09-11
Upgrades
Hold
to
Strong Buy
Reason
TD Cowen
Steve Scala
Strong Buy
Maintains
$90 → $95
2024-08-12
Reason
TD Cowen
Steve Scala
Price Target
$90 → $95
2024-08-12
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AstraZeneca PLC (AZN.O) is 15.75, compared to its 5-year average forward P/E of 18.31. For a more detailed relative valuation and DCF analysis to assess AstraZeneca PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
18.31
Current PE
15.75
Overvalued PE
21.19
Undervalued PE
15.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
14.37
Current EV/EBITDA
12.48
Overvalued EV/EBITDA
15.99
Undervalued EV/EBITDA
12.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
4.30
Current PS
3.86
Overvalued PS
4.74
Undervalued PS
3.86

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 166.61% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

AZN News & Events

Events Timeline

(ET)
2025-06-17
09:58:26
Trump administration weighs crackdown on pharma ads, Bloomberg says
select
2025-06-13 (ET)
2025-06-13
06:25:13
AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals
select
2025-06-12 (ET)
2025-06-12
12:40:51
Senators to propose ban on drug ads to consumers, WSJ reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
05:16 AMYahoo Finance
Trump's big beautiful bill: What the pharma industry is watching
  • Pharmaceutical Stocks Decline: Major pharmaceutical companies like Pfizer, Johnson & Johnson, and Abbvie are experiencing stock declines following President Trump's announcement of impending tariffs on the industry.

  • Healthcare Policy Insights: Chris Meekins discusses potential impacts of healthcare legislation, highlighting changes to Medicaid provider taxes and the implications for state budgets, while expressing skepticism about the accuracy of CBO enrollment projections.

Preview
5.0
02:00 AMNASDAQ.COM
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
  • Gardasil Sales Decline: Merck's Gardasil vaccine sales have significantly dropped, particularly in China due to economic slowdown, with a 40% year-over-year decline in Q1 2025 and a decision to halt shipments to manage inventory levels. Despite this, sales remain strong in other regions like the U.S. and Japan.

  • New Product Launch and Competition: Merck has received FDA approval for its RSV prevention monoclonal antibody, Enflonsia, expected to launch ahead of the 2025-26 season; however, it will face competition from AstraZeneca/Sanofi's Beyfortus, which achieved blockbuster status in its first year.

Preview
9.0
06-17CNBC
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
  • Advancements in Cancer Treatment: Antibody-drug conjugates (ADCs) are emerging as a promising alternative to traditional chemotherapy, delivering targeted treatment directly to cancer cells while minimizing damage to healthy cells. Major pharmaceutical companies are investing heavily in ADC development, with some showing potential to replace chemotherapy in specific cases.

  • Challenges and Future Directions: Despite progress, challenges remain in optimizing ADCs, such as controlling the release of toxic payloads and identifying effective cancer targets. Ongoing research aims to refine these treatments and explore combination therapies that could enhance efficacy and safety in cancer care.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AstraZeneca PLC (AZN) stock price today?

The current price of AZN is 70.97 USD — it has decreased -3.51 % in the last trading day.

arrow icon

What is AstraZeneca PLC (AZN)'s business?

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

arrow icon

What is the price predicton of AZN Stock?

Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 87.14 USD with a low forecast of 75.00 USD and a high forecast of 97.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AstraZeneca PLC (AZN)'s revenue for the last quarter?

AstraZeneca PLC revenue for the last quarter amounts to 13.59B USD, increased 7.17 % YoY.

arrow icon

What is AstraZeneca PLC (AZN)'s earnings per share (EPS) for the last quarter?

AstraZeneca PLC. EPS for the last quarter amounts to 1.87 USD, increased 33.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for AstraZeneca PLC (AZN)'s fundamentals?

The market is revising Upward the revenue expectations for AstraZeneca PLC (AZN) for FY2025, with the revenue forecasts being adjusted by 0.87% over the past three months. During the same period, the stock price has changed by -8.27%.
arrow icon

How many employees does AstraZeneca PLC (AZN). have?

AstraZeneca PLC (AZN) has 94300 emplpoyees as of June 18 2025.

arrow icon

What is AstraZeneca PLC (AZN) market cap?

Today AZN has the market capitalization of 220.10B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free